[Skip to Content]
[Skip to Content Landing]
Citations 0
October 5, 2005

Tirofiban Plus Sirolimus-Eluting Stent vs Abciximab Plus Bare-Metal Stent—Reply

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;294(13):1616-1618. doi:10.1001/jama.294.13.1617-b

In Reply: We agree with some of the comments raised by Dr Osman and colleagues, as we noted in the discussion of the limitations of our study. Among available glycoprotein IIb/IIIa inhibitors, Abciximab is the agent of choice in the context of primary intervention. When administered in the catheterization laboratory, abciximab, which provides rapid and complete antiplatelet effect, has been shown to be superior to tirofiban when administered as a 10-μg/kg bolus.1 When tirofiban is administered at this dose, the level of platelet inhibition reached after 10 to 15 minutes is suboptimal compared to that achieved using abciximab.